as 09-06-2024 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Founded: | 1887 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 95.4B | IPO Year: | N/A |
Target Price: | $56.50 | AVG Volume (30 days): | 10.2M |
Analyst Decision: | Hold | Number of Analysts: | 17 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | -3.22 | EPS Growth: | N/A |
52 Week Low/High: | $39.35 - $61.43 | Next Earning Date: | 10-24-2024 |
Revenue: | $46,509,000,000 | Revenue Growth: | 2.93% |
Revenue Growth (this year): | 5.04% | Revenue Growth (next year): | -0.13% |
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Zacks
a day ago
Business Wire
2 days ago
Zacks
2 days ago
Insider Monkey
2 days ago
Zacks
3 days ago
Reuters
5 days ago
Motley Fool
5 days ago
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.